 |
|
|
|
|
|
|
|
 |
 |
|
|
|
Telomelysin® OBP-301 (Telomelysin®), our lead compound for the treatment of cancer, is in Phase-I clinical development in the US and is being tested for various solid tumors.
FESTINAVIR®(OBP-601), our lead compound for infectious disease, is in late pre-clinical (IND stage) for HIV/AIDS therapy. OBP-601 is a novel NRTI with highly promising safety and resistance profiles.
Telomescan® (OBP-401), our novel cancer diagnostic compound, is in a validation stage (feasibility assessment) and is expected to be effective in detecting most types of cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Copyright
(c)2004-2005, Oncolys BioPharma Inc. All rights reserved.
|
|
